Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
ORIC on Nasdaq
Shares outstanding
98,489,676
Price per share
$8.18
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
106,492,098
Total reported value
$1,277,897,890
% of total 13F portfolios
0%
Share change
+12,976,649
Value change
+$159,574,070
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
151
Price from insider filings
$9.06
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VIKING GLOBAL INVESTORS LP 10% +8.8% $89,563,080 +$22,127,178 8,729,345 +33% VIKING GLOBAL INVESTORS LP 30 Jun 2025
Nextech Crossover I GP S.a r.l. 8.4% $73,488,656 7,162,637 Nextech Crossover I GP S.a. r.l. 30 Jun 2025
EcoR1 Capital, LLC 6.9% $35,726,296 6,728,116 EcoR1 Capital, LLC 29 Jul 2025
Venrock Healthcare Capital Partners III, L.P. 7.7% +64% $35,029,459 +$18,130,241 6,596,885 +107% Venrock Healthcare Capital Partners III, L.P. 08 Apr 2025
SR ONE CAPITAL MANAGEMENT, LLC 4.8% -13% $47,353,840 4,615,384 0% SR One Capital Management, LLC 12 Aug 2025
ALKEON CAPITAL MANAGEMENT LLC 4.6% $54,049,152 4,504,096 Alkeon Capital Management LLC 30 Sep 2025
Point72 Asset Management, L.P. 5.1% $45,161,021 4,401,659 Point72 Asset Management, L.P. 29 May 2025
COLUMN GROUP II, LP 3.7% $48,612,534 3,644,118 Peter Svennilson 30 Sep 2025
BlackRock, Inc. 4.2% $19,223,389 3,620,224 BlackRock, Inc. 30 Jun 2025
FMR LLC 3.5% $12,141,619 2,467,809 FMR LLC 31 Dec 2024
Frazier Life Sciences Public Fund, L.P. 2% $6,938,150 1,410,193 James N. Topper 31 Mar 2025
As of 30 Sep 2025, Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) has 151 institutional shareholders filing 13F forms. They hold 106,492,098 shares. .

Top 25 institutional shareholders own 90% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Nextech Invest, Ltd. 7.3% 7,162,637 0% 13% $85,951,644
EcoR1 Capital, LLC 6.8% 6,728,116 +316% 3.9% $80,737,392
VR ADVISER, LLC 6.7% 6,596,885 0% 4.5% $79,162,620
VIKING GLOBAL INVESTORS LP 6.7% 6,572,700 0% 0.2% $78,872,400
Pfizer Inc 5.5% 5,376,344 0% 15% $64,516,128
BlackRock, Inc. 5.4% 5,276,620 +29% 0% $63,319,440
VANGUARD GROUP INC 4.7% 4,650,138 +49% 0% $55,801,656
SR One Capital Management, LP 4.6% 4,514,929 0% 7.8% $54,179,148
ALKEON CAPITAL MANAGEMENT LLC 4.6% 4,504,096 0% 0.24% $54,049,152
NEA Management Company, LLC 4.2% 4,118,621 0% 2.7% $49,423,452
ORBIMED ADVISORS LLC 3.7% 3,641,756 +305% 1% $43,701,072
Column Group LLC 3.6% 3,540,777 0% 52% $42,489,324
Vivo Capital, LLC 3.2% 3,126,604 0% 3% $37,519,248
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 2,871,327 +3.9% 0% $34,457,000
Point72 Asset Management, L.P. 2.7% 2,619,914 -8.1% 0.07% $31,438,968
FMR LLC 2.6% 2,528,048 +2.3% 0% $30,336,576
STATE STREET CORP 2.4% 2,403,939 +47% 0% $28,847,268
First Turn Management, LLC 2.2% 2,159,474 +7.4% 3.9% $25,913,688
SILVERARC CAPITAL MANAGEMENT, LLC 2% 1,948,808 +8.2% 3.4% $23,385,696
MPM BIOIMPACT LLC 1.8% 1,729,378 0% 3.4% $20,752,536
GEODE CAPITAL MANAGEMENT, LLC 1.7% 1,630,744 +47% 0% $19,573,783
Balyasny Asset Management L.P. 1.5% 1,519,314 -15% 0.04% $18,231,768
ROYCE & ASSOCIATES LP 1.5% 1,458,483 +521% 0.17% $17,501,796
JPMORGAN CHASE & CO 1.2% 1,228,528 -8% 0% $14,742,336
CITADEL ADVISORS LLC 1.2% 1,198,004 -15% 0.01% $14,376,048

Institutional Holders of Oric Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ORIC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 42,239 $346,005 +$47,889 818.09% 3
2025 Q3 106,492,098 $1,277,897,890 +$159,574,070 1,200% 151
2025 Q2 93,349,298 $947,499,065 +$169,716,846 1,015% 140
2025 Q1 79,209,337 $442,005,240 +$11,923,653 558% 142
2024 Q4 75,794,185 $611,682,286 -$16,308,142 807% 129
2024 Q3 69,823,199 $715,076,222 +$22,599,735 1,025% 121
2024 Q2 67,581,249 $477,801,725 +$16,918,129 707% 111
2024 Q1 61,522,206 $845,930,302 +$182,999,091 1,375% 93
2023 Q4 16,457 $151,404 -$189,662 920% 1
2023 Q3 48,053,106 $290,723,330 +$14,140,743 605% 89
2023 Q2 45,537,877 $353,374,807 +$99,053,472 776% 83
2023 Q1 33,075,099 $188,527,951 +$3,379,925 570% 70
2022 Q4 32,430,291 $192,141,081 -$463,484 589% 64
2022 Q3 32,701,288 $104,643,704 -$1,676,650 320% 69
2022 Q2 32,836,960 $147,125,000 -$5,569,766 448% 75
2022 Q1 31,462,589 $167,970,917 -$6,985,117 534% 91
2021 Q4 32,408,019 $476,115,938 -$54,519,859 1,470% 75
2021 Q3 36,405,513 $761,744,855 +$8,529,738 2,091% 80
2021 Q2 36,145,561 $639,409,737 -$3,016,892 1,769% 78
2021 Q1 34,481,967 $844,794,848 +$63,249,843 2,449.98% 81
2020 Q4 32,486,547 $1,099,708,951 +$273,809,943 3,385% 74
2020 Q3 22,151,946 $552,858,000 +$7,639,740 2,500.85% 52
2020 Q2 21,388,813 $718,339,063 +$718,339,299 3,373% 64